Gastrointestinal involvement in systemic sclerosis;Atteinte digestive au cours de la sclérodermie systémique

Presse Medicale

Volumn 35, Issue 12 C2, 2006, Pages 1952-1965

  Marie, Isabelle ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Centre Expert Associe du Centre de Reference National Sclerodermies Systemiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; APREPITANT; DOMPERIDONE; ERYTHROMYCIN; LAXATIVE; METOCLOPRAMIDE; OCTREOTIDE; PROTON PUMP INHIBITOR; PRUCALOPRIDE; STOMACH SECRETION INHIBITOR;

ABDOMINAL RADIOGRAPHY; ANORECTAL DISEASE; BARRETT ESOPHAGUS; CLINICAL FEATURE; COLON DISEASE; COLONOSCOPY; CONSTIPATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIGESTIVE TRACT ENDOSCOPY; DYSPEPSIA; DYSPHAGIA; ELECTROGASTROGRAPHY; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS MANOMETRY; ESOPHAGUS SCINTISCANNING; ESOPHAGUS STENOSIS; ESOPHAGUS STRICTURE; FEEDBACK SYSTEM; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE OBSTRUCTION; INTESTINE TRANSIT TIME; LIVER DISEASE; MALABSORPTION; MOTOR DYSFUNCTION; PNEUMATOSIS INTESTINALIS; PREVALENCE; PROGNOSIS; RADIODENSITOMETRY; REVIEW; STOMACH DISEASE; SYSTEMIC SCLEROSIS;

EID: 33845497184     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74930-2     Document Type: Review

References (93)

1. Jiranek GC, Bredfelt JE. Organ involvement: gut and hepatic manifestations: In: Clements PJ, Furst DE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 453-82.
2. Marie I. Atteinte digestive au cours de la sclérodermie systémique. Rev Med Interne. 2002; 23 (Suppl 1): 19-20.
3. Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001; 45; 346-54.
4. Marie I, Levesque H, Dominique S, Hatron PY, Michon-Pasturel U, Remy-Jardin M, Courtois H. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie I. Pneumopathie interstitielle chronique fibrosante. Rev Med Interne. 1999; 20: 1004-16.
5. Marie I, Levesque H, Ducrotté P, Courtois H. Atteinte de l'intestin grêle au cours de la sclérodermie systémique. Rev Med Interne. 1999; 20: 504-13.
6. Marie I, Levesque H, Ducrotté P, Denis P, Benichou J, Hellot MF et al. Manometry of the upper intestinal tract in patients with systemic sclerosis. A prospective study. Arthritis Rheum. 1998; 41: 1874-83.
7. Marie I, Levesque H, Ducrotté P, Denis P, Hellot MF, Benichou J et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001; 96: 77-83.
8. Marie I, Levesque H, Hatron PY, Dominique S, Courtois H. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire. Rev Med Interne. 1999; 20: 1017-27.
9. Rodnan GP, Fennel RH. Progressive systemic sclerosis sine scleroderma. JAMA. 1962; 180: 665-70.
10. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum. 1994; 24: 29-39.
11. Cohen S, Laufer I, Snape WJ, Shiau YF, Levine GM, Jimenez S. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology. 1980; 79: 155-66.
12. Lock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997; 92: 763-71.
13. Marie I, Levesque H, Tranvouez JL, François A, Riachi G, Cailleux N et al. Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology. 2001; 40: 102-6.
14. Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972; 58: 30-44.
15. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998; 27: 563-94.
16. Sjögren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994; 37: 1265-82.
17. Sjögren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 569-75.
18. Young MA, Rose S, Reynolds JC. Gastrointestinal manifestations of scleroderma. Rheum Dis Clin North Am. 1996; 22: 797-823.
19. Kinder RR, Fleischmajer R. Systemic scleroderma: A review of organ systems. Int J Dermatol. 1974; 13: 382-95.
20. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991; 34: 403-13.
21. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998; 57: 682-6.
22. Mayes MD, Lacey Jr JV, Beebe-Dimmer J, Gillepsie BW, Cooper B, Laing TJ et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48: 2246-55.
23. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TJ, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971; 75: 369-76.
24. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis of features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002; 81: 154-67.
25. Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology. 1989; 96: 110-5.
26. Prescott RJ, Fremont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992; 166: 255-63.
27. Kaye SA, Seifalian AM, Lim SG, Hamilton G, Black CM. Ischemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy? Q J Med. 1994; 87: 495-500.
28. Quarto di Palo F, Rivolta R, Berruti V, Caronni M, Bazzi S, Scorza R. Superior mesenteric artery blood flow in systemic sclerosis patients. Rheumatology. 2002; 41: 730-4.
29. DiMarino AJ, Carlson G, Myers A, Schumacher HR, Cohen S. Duodenal myoelectric activity in scleroderma: abnormal responses to mechanical and hormonal stimuli. N Engl J Med. 1973; 289: 1220-3.
30. D'Angelo WA, Fries JF, Masi AT, Schulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969; 46: 428-40.
31. Hendel L, Kobayashi T, Petri M. Ultrastructure of the small intestinal mucosa in progressive systemic sclerosis (PSS). Acta Pathol Microbiol Immunol Scand Sect A. 1987; 95: 41-6.
32. Bloch F, Le Porc J, Mallet L, Fiessinger JN, Housset E, Petite JP. Pneumopéritoine spontané au cours de la sclérodermie. Gastroentérol Clin Biol. 1984; 8: 557-9.
33. Treacy WL, Baggenstoss AH, Slocumb CH, Code CF. Scleroderma of the esophagus. A correlation of histologic and physiologic findings. Ann Intern Med. 1963; 59: 351-6.
34. Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-controlled study of the pathology of oesophageal disease in systemic sclerosis. Gut. 2006 (on line)
35. Akesson WA, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989; 28: 281-6.
36. Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994; 39: 2209-15.
37. Villadsen GE, Storkholm J, Zachariae H, Hendel L, Bendtsen F, Gregersen H. Oesophageal pressure-cross-sectional area distributions and secondary peristalsis in relation to subclassification of systemic sclerosis. Neurogastroenterol Motil. 2001; 13: 199-210.
38. Zamost BJ, Hirschberg J, Ippoliti AF, Furst DE, Clements PJ, Weinstein WM. Esophagitis in scleroderma: prevalence and risk factors. Gastroenterology. 1987; 92: 421-8.
39. Katzka DA, Reynolds JC, Saul SH, Plotkin A, Lang CA, Ouyang A et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987; 82: 46-52.
40. Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med. 1989; 149: 589-93.
41. Reynolds TB, Denison EK, Frankl HD, Lieberman FL, Peters RL. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med. 1971; 50: 302-12.
42. Chami TN, Nikoomanesh P, Katz PO. An unusual presentation of pill-induced esophagitis. Gastrointest Endosc. 1995; 42: 263-5.
43. Hendel L, Svejgaard E, Walsoe I, Kieffer M, Stenderup A. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol. 1988; 23: 1182-6.
44. Yarze JC, Varga J, Stampfl D, Castell DO, Jimenez SA. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol. 1993; 88: 870-6.
45. Maddern GJ, Horowitz M, Jamieson GG, Chetterton BE, Collin PJ, Roberts-Thomson P. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology. 1984; 87: 922-6.
46. Murphy JR, McNally P, Peller P, Shay SS. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci. 1992; 37: 833-41.
47. Edenbrandt L, Theander E, Hogstrom M, Scheja A, Akesson A, Palmer J. Esophageal scintigraphy of systemic sclerosis. J Nucl Med 1995; 36: 1533-8.
48. Baron M, Arzoumanian A. Radionuclide esophageal transit studies in progressive systemic sclerosis: an analysis of longitudinal data. J Rheumatol. 1991; 18: 1837-40.
49. Recht MP, Levine MS, Katzka DA, Reynolds JC, Saul SH. Barrett's esophagus in scleroderma: increased prevalence and radiographic findings. Gastrointest Radiol. 1988; 13 : 1-5.
50. Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther. 1992; 6: 565-77.
51. Sallam H, McNearney TA, Chen JDZ. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006; 23: 691-712.
52. Bortolotti M, Turba E, Tosti A, Sarti P, Brunelli F, Del Campo L et al. Gastric emptying and interdigestive antroduodenal motility in patients with esophageal scleroderma. Am J Gastroenterol. 1991; 86: 743-7.
53. Marie I, Cailleux N, Hochain P, François A, Metayer J, Levesque H et al. Doit-on considérer l'estomac pastèque comme une localisation méconnue de la sclérodermie? J Mal Vasc. 1996; 21: 188-91
54. Marie I, Cailleux N, Levesque H. Watermelon stomach and systemic sclerosis: localization of digestive system involvement? Arthritis Rheum. 1996; 39: 1439.
55. Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am J Gastroenterol. 1998; 93: 1453-6.
56. Calamia KT, Scolapio JS, Viggiano TR. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clin Exp Rheumatol. 2000; 18: 605-8.
57. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of gastrointestinal dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002; 97: 194-7.
58. Fiorucci S, Distrutti V, Gerli R, Morelli A. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol. 1994; 89: 550-5.
59. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995; 40: 1892-901.
60. Rees WDW, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology. 1982; 83: 575-80.
61. Gough A, Andrews D, Bacon PA, Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995; 34: 976-7.
62. Marguerie C, Kaye S, Vyse T, MacKworth-Young C, Walport MJ, Black C. Malabsorption caused by celiac disease in patients who have scleroderma. Br J Rheumatol. 1995; 34: 858-61.
63. Greenberger NJ, Dobbins WD, Ruppert RD, Jesseph JE. Intestinal atony in progressive systemic sclerosis (scleroderma). Am J Med. 1968; 45: 301-8.
64. Bluestone R, MacMahon M, Dawson JM. Systemic sclerosis and small bowel involvement. Gut 1969; 10: 185-93.
65. Galandiuk S, Fazio VW. Pneumatosis cystoides intestinalis: a review of the literature. Dis Colon Rectum. 1986; 29: 358-63.
66. Sequeira W. Pneumatosis cystoides intestinalis in systemic sclerosis and other diseases. Semin Arthritis Rheum. 1990; 19: 269-77.
67. Stafford-Brady FJ, Kahn HJ, Ross TM, Russell ML. Advanced scleroderma bowel: complications and management. J Rheumatol. 1988; 15: 869-74.
68. Battle WM, McLean GK, Brooks JJ, Herlinger H, Trotman BW. Spontaneous perforation of the small intestine due to scleroderma. Dig Dis Sci. 1979; 24: 80-4.
69. Hendy MS, Torrance HB, Warnes TW. Small-bowel volvulus in association with progressive systemic sclerosis. Br Med J. 1979; 1: 1051-2.
70. MacMahon HE. Systemic scleroderma and massive infarction of intestine and liver. Surg Gynecol Obstet. 1972; 134: 10-4.
71. Grabowski G, Grant JP. Nutritional support in patients with systemic scleroderma. JPEN. 1989; 13: 147-51.
72. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991; 325: 1461-7.
73. Malcolm A, Ellard K. Intestinal perforation associated with octreotide therapy in scleroderma. Am J Gastroenterol 2001; 96: 3206-8.
74. Yarze JC, Chase MP. Free intra-abdominal gas associated with octreotide use: intestinal perforation or benign pneumoperitoneum associated with underlying systemic sclerosis? Am J Gastroenterol. 2002; 97: 1844-5.
75. Ng SC, Clements PJ, Berquist WE, Furst DE, Paulus HE. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease. Arthritis Rheum. 1989; 32: 122-6.
76. Trezza M, Krogh K, Egekvist H, Bjerring P, Luarberg S. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol. 1999; 34: 409-13.
77. Madsen JL, Hendel L. Gastrointestinal transit times of radiolabeled meal in progressive systemic sclerosis. Dig Dis Sci. 1992; 37: 1404-8.
78. Grasland A, Pouchot J, Leport J, Barge J, Vinceneux P. Pneumatose kystique intestinale. Presse Med. 1998; 27: 1804-12.
79. Lindsey I, Farmer CR, Cunningham IG. Subtotal colectomy and cecosigmoid anastomosis for colonic systemic sclerosis: report of a case and review of the literature. Dis Colon Rectum. 2003; 46: 6-1706-11.
80. Leighton JA, Valdovinos MA, Pemberton JH, Rath DM, Camilleri M. Anorectal dysfunction and rectal prolapse in progressive sytemic sclerosis. Dis Colon Rectum 1993; 36: 182-5.
81. Singh D, Shill M, Kaur H. The watermelon rectum. J Clin Gastroenterol. 2001; 33: 164-6.
82. Frieling T, Enck P, Bremer G, Lubke HJ, Berges W, Wienbeck M. Anorectal motility in systemic scleroderma. Gastroenterology. 1988; 26: 689-93.
83. Hamel-Roy J, Devroede G, Arhan P, Tetreault L, Duranceau A, Ménard H. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 1985; 88: 1-7.
84. Engel AF, Kamm MA, Talbot IC. Progressive systemic sclerosis of the internal anal sphincter leading to passive fecal incontinence. Gut 1994; 35: 857-9.
85. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002; 51: 881-3.
86. Murray-Lyon IM, Thompson RPH, Ansell ID, Williams R. Scleroderma and primary biliary cirrhosis. Br Med J. 1970; 3: 258-9.
87. Miller MH, Littlejohn GO, Davidson A, Jones B, Topliss DJ. The clinical significance of the anticentromere antibody. Br J Rheumatol. 1987; 26: 17-21.
88. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc. 1982; 57: 365-70.
89. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006; 55: 388-94.
90. Umeyama K, Yui S, Fukamizy A, Yoshikawa K, Yamashita T. Idiopathic portal hypertension associated with progressive systemic sclerosis. Am J Gastroenterol. 1982; 77: 645-8.
91. Lurie B, Novis B, Bank S, Siver W, Botha JBC, Marks IN. CRST syndrome and nodular transformation of the liver. Gastroenterology. 1973; 64: 457-61.
92. MacMahon RFT, Babbs C, Warnes TW. Nodular regenerative hyperplasia of the liver CREST syndrome and primary biliary cirrhosis: an overlap syndrome? Gut. 1989; 30: 1430-3.
93. Hendel L, Worning H. Exocrine pancreatic function in patients with progressive systemic sclerosis. Scand J Gastroenterol. 1989; 24: 461-6.